CA-EVIDATION
16.11.2023 15:01:58 CET | Business Wire | Press release
Evidation — the company creating new ways to measure and improve health in everyday life — today announced a landmark partnership with Our Future Health, a national health research initiative and collaboration between the UK’s National Health Service (NHS), public health agencies, non-profits, and leading life sciences companies. Our Future Health will deploy Evidation’s enterprise digital health engagement and measurement platform to conduct a multi-year, longitudinal research program for up to five million participants across the UK.
“Evidation and Our Future Health believe that deeply understanding individuals' everyday health experiences can accelerate discoveries that will transform health," said Christine Lemke, Co-founder and CEO of Evidation. "Together, with the participation of millions of volunteers across the UK, we will enable research that can advance more inclusive and effective ways to prevent, detect, and treat disease."
“Our Future Health aims to be a world-leading resource for health research,” said Dr Raghib Ali OBE, Chief Executive of Our Future Health. “Evidation has extensive expertise measuring and characterizing health in everyday life and engaging people at scale. This, combined with their experience in deploying large research and engagement programs and their shared commitment to the highest standards of data protection and user privacy, makes them the ideal partner for Our Future Health.”
Our Future Health is bringing together up to five million people to develop new ways to prevent, detect and treat diseases. To achieve this, Our Future Health will recruit a diverse and inclusive cohort of people across the UK who have consented to participate. The program population accounts for almost 10% of the UK’s adult population of over 53 million people. Evidation’s technology will power the digital experience, including a participant-facing app and technology infrastructure, that makes this massive research initiative possible. This new digital experience will be developed in the coming months.
Evidation’s platform is the technology layer that powers health research and engagement programs for some of the world’s leading healthcare organizations. Evidation makes it possible to harness real-world data — including wearables and survey data — to deeply understand health experiences rapidly and longitudinally, in large populations. Refined over a decade, Evidation’s measurement and engagement platform helps capture health data from outside the clinic and rewards participants for taking healthy actions.
About Evidation
Evidation creates new ways to measure and improve health in everyday life — making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe. Learn more at www.evidation.com.
About Our Future Health
Our Future Health is a collaboration between the public, private and charity sectors. It aims to be the UK’s largest health research program, bringing people together to develop new ways to prevent, detect and treat disease.
Our Future Health is committed to the highest standards, policies and processes that protect participants’ confidentiality, whilst maximizing the opportunity to help researchers to tackle serious diseases. Participants’ data is de-identified and held securely in trusted research environments that meet strict security criteria. There is a robust and transparent access process to ensure appropriate research access to Our Future Health data and samples for registered researchers. All researchers are held to the same standards.
Our Future Health is a member of the UK Health Data Research Alliance, the independent alliance of leading healthcare and research organizations establishing best practice for the ethical use of UK health data for research at scale.
Our Future Health is a company limited by guarantee registered in England and Wales (number 12212468) and a charity registered with the Charity Commission for England and Wales (charity number 1189681) and OSCR, Scottish Charity Regulator (charity number SC050917).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116712663/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oral‑B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability‑Focused Oral Health Studies13.5.2026 09:06:00 CEST | Press release
Oral‑B and iADH build on four years of action to advance inclusive oral care and whole‑body health41% of Europeans identify as living with a disability, representing a four‑point increase wave‑on‑wave Oral‑B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Health (iADH). The new phase introduces Project Steady, one of Europe’s largest real‑world studies exploring oral care experiences among people with disabilities, their carers and dental professionals. The programme aims to reduce everyday barriers to oral care through inclusive design, evidence-based research and professional education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511175864/en/ Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Health Studies Oral health for Whole-Bo
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 08:38:00 CEST | Press release
FY2025 Pipeline Successes Set the Stage for Pivotal Product LaunchesAchieved Latest FY2025 Management GuidanceTakeda is Entering a New Era & Transforming for Growth Acceleration Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amo
Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 07:20:00 CEST | Press release
1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was str
Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 07:00:00 CEST | Press release
18MW AI-ready facility developed in partnership with DC Max, a French data center developer with a 1GW pipeline Partnership provides preferential access to DC Max’s development pipeline, accelerating Phoenix’s goal towards an excess of 1GW global AI and HPC platform across Europe and the GCC Phoenix has already acquired the land for the Lyon site, which comes with secured permits, grid connection in place and available power, enabling construction to begin in July 2026, with delivery targeted between Q4 2027 and Q1 2028 Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, d
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 07:00:00 CEST | Press release
Agreement includes license for Owkin’s AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly analyze and forecast the competitive landscape for specific pharmaceutical targets, assets, and trials. Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
